Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

148.80 +2.44 (+1.67%)
Streaming Delayed Price Updated: 1:42 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Comparing Johnson &amp; Johnson With Industry Competitors In Pharmaceuticals Industry
Via Benzinga
Investor Alert: Are These 3 Spinoff Stocks Destined to Sizzle or Fizzle?
Investors often wonder what to make of spinoff stocks with these three recent moves to watch providing varying outcomes and future potential. 
Via InvestorPlace
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
After a painful two-year selloff, Pfizer shareholders may have finally gained a foothold after the company delivered a solid Q1 2024 earnings report 
Via MarketBeat
Exposures COVID-19
Johnson & Johnson: A Healthcare Giant That's Looking More Attractive By The Day
Johnson & Johnson is the largest healthcare products firm in the world by sales, spanning pharmaceuticals, medical devices, and consumer products. Plus, its shares only look more attractive as time... 
Via Talk Markets
Intuitive Surgical Builds On Its Robotic Surgery Prowess. But Challengers Are Coming.
As new robotic surgery systems loom, Intuitive Surgical investors await a "game-changer." 
Via Investor's Business Daily
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
Via Benzinga
Johnson & Johnson Stock: Buy, Sell, or Hold?
Is this top healthcare stock worth adding to your portfolio today? 
Via The Motley Fool
3 Dividend Growth Stocks that Just Raised Their Payouts
One of these stocks boosted its payouts by as much as 13%. 
Via The Motley Fool
Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks 'No Cut' Scenario May Not Be Negative For Market
U.S. stocks look to push ahead on a positive path, now that the Federal Reserve’s rate decision is in the rearview mirror. Major index futures point to a positive open on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Stock Market Crash Alert: 3 Must-Buy Healthcare Stocks When Prices Plunge
Investors should look for opportunities to buy these leading healthcare companies, each of which posted strong Q1 results. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: DecisionPoint Systems, Inc. (NYSE American - DPSI), AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Macatawa Bank Corporation (Nasdaq - MCBC), Shockwave Medical,
From Brodsky & Smith LLC
Via GlobeNewswire
Johnson & Johnson Wants To Deal With Talc Lawsuit Overhang, Proposes $6.5B Settlement Package
Johnson & Johnson announces $6.475 billion settlement for talc-related ovarian cancer lawsuits. Details on proposed resolution. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Dow Jones Industrial Average Struggles To Recover From Recent Backslide As Fed Rounds Corner
After this week's backslide, the Dow Jones Industrial Average (DJIA) is stuck in a rut, dragging the index below 38,000.00 as investors buckle down for another rate call from the US Federal Reserve... 
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Cannabis Stocks CGC, ACB, TLRY Drop After Huge Rescheduling Rally
Cannabis stocks are falling on Wednesday as shares of marijuana companies are giving up some of the massive gains they saw yesterday. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
Why Is CytomX (CTMX) Stock Up 180% Today?
CytomX stock is rising higher on Wednesday as CTMX investors get an update on its upcoming earnings and clinical trial news. 
Via InvestorPlace
JNJ Stock: J&J Proposes $6.5 Billion Settlement for Talc Cancer Lawsuits
Johnson & Johnson stock is up on Wednesday as JNJ investors learn of plans for a $6.5 billion settlement to its talc lawsuits. 
Via InvestorPlace
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization
From Johnson & Johnson
Via Business Wire
3 No-Brainer Stocks to Buy With $200 Right Now
You don't need a mountain of cash to grow your wealth on Wall Street. 
Via The Motley Fool
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Healthcare Stocks
These are the list of healthcare stocks to avoid that present challenges indicating signs of a crash in the near future. 
Via InvestorPlace
3 Stocks Mega Investors Are Buying
Three stocks became top choices for some of Wall Street's biggest investors. Each carrying their own merit, they all offer double-digit upside 
Via MarketBeat
Topics Regulatory Compliance
Exposures Legal Regulatory
Slump Survivors: 3 Stocks That Will Outlast the S&P 500 Downturn
Discover how these stocks may progress in consumer staples, health care, and tech sectors and outperform the S&P 500. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Cutting Edge Picks: 3 Med Tech Stocks With Room to Run
The med tech stocks are worth checking out for value investors seeking potentially overlooked growth catalysts. 
Via InvestorPlace
Johnson & Johnson-Partnered Addex Therapeutics' Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks
Latest Phase 2 epilepsy study findings on ADX71149 adjunctive therapy for focal onset seizures. Partnered with Janssen, Addex Therapeutics evaluates treatment efficacy in patients with suboptimal... 
Via Benzinga
Johnson & Johnson Is a King of Dividend Safety
The healthcare behemoth has fortified its dividend. 
Via The Motley Fool
7 Retirement Stocks to Buy at a 52-Week Low in April
One of the best ways to keep your portfolio safe while generating income is with dividend-paying retirement stocks at 52-week lows. 
Via InvestorPlace
Topics Retirement
Exposures Pension
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
The first-quarter 2024 earnings season picked up pace this week, with Merck, Sanofi, Novartis, and AstraZeneca announcing their first-quarter results. Three of the four companies beat estimates for... 
Via Talk Markets
2 Top Growth Stocks to Buy Right Now and Hold Forever
These healthcare stocks can provide enviable long-term portfolio growth. 
Via The Motley Fool
Better Dividend Stock: AbbVie or Johnson & Johnson?
One thing is for sure: Dividend seekers can't go wrong with either. 
Via The Motley Fool
5 Stocks In Focus On Their Recent Dividend Hikes
Wall Street’s impressive bull run for the last 15 months has been facing severe hurdles in April. In such an environment, it may be prudent to consider stocks that consistently deliver dividends. Here... 
Via Talk Markets
7 Stocks to Buy if Inflation Continues to Reign in 2024
The latest inflation readings showed consumers won't get low prices anytime soon, here are seven stocks to buy if inflation continues to rise 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.